MGUS
MCID: MNC006
MIFTS: 44

Monoclonal Gammopathy of Uncertain Significance (MGUS) malady

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Monoclonal Gammopathy of Uncertain Significance

Aliases & Descriptions for Monoclonal Gammopathy of Uncertain Significance:

Name: Monoclonal Gammopathy of Uncertain Significance 12 14
Monoclonal Gammopathy of Undetermined Significance 12 50 69
Mgus 12 50

Classifications:



External Ids:

Disease Ontology 12 DOID:7442
ICD10 33 D47.2

Summaries for Monoclonal Gammopathy of Uncertain Significance

NIH Rare Diseases : 50 monoclonal gammopathy of undetermined significance (mgus) is a condition in which an abnormal protein called monoclonal protein is detected in the blood. mgus typically does not cause any problems, although some affected people may experience numbness, tingling or weakness. in some cases, mgus may progress over time to certain forms of blood cancer (such as multiple myeloma, macroglobulinemia, or b-cell lymphoma). mgus is thought to be a multifactorial condition that is likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. people with mgus are usually monitored closely to ensure that the levels of monoclonal protein do not rise and other problems do not develop. those with stable levels of monoclonal protein typically do not require treatment. last updated: 12/27/2016

MalaCards based summary : Monoclonal Gammopathy of Uncertain Significance, also known as monoclonal gammopathy of undetermined significance, is related to vps11-related autosomal recessive hypomyelinating leukodystrophy and dyslexia 5. An important gene associated with Monoclonal Gammopathy of Uncertain Significance is IL6 (Interleukin 6), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs Liraglutide and Hormone Antagonists have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and testes, and related phenotypes are cellular and homeostasis/metabolism

Wikipedia : 71 Monoclonal gammopathy of undetermined significance (MGUS, unknown or uncertain may be substituted for... more...

Related Diseases for Monoclonal Gammopathy of Uncertain Significance

Diseases related to Monoclonal Gammopathy of Uncertain Significance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 186)
id Related Disease Score Top Affiliating Genes
1 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.3 IL6 TNF
2 dyslexia 5 10.3 IL6 TNF
3 alcoholic neuropathy 10.3 CD40LG CD79A
4 camptodactyly vertebral fusion 10.3 CD40LG CD79A
5 aortic atherosclerosis 10.3 IL6 TNF
6 spinal polio 10.3 CD40LG CD79A
7 rabies 10.3 CD40LG CD79A
8 unilateral retinoblastoma 10.3 CD40LG CD79A
9 degenerative disc disease 10.3 IL6 TNF
10 mesangial proliferative glomerulonephritis 10.3 CD40LG CD79A
11 delta chain disease 10.3 CD40LG CD79A
12 discitis 10.3 CD40LG CD79A
13 spinal canal and spinal cord meningioma 10.3 CD40LG CD79A
14 trichostrongyloidiasis 10.3 CD40LG CD79A
15 colloid adenoma 10.3 CD40LG CD79A
16 heart septal defect 10.3 CD40LG CD79A
17 cutaneous polyarteritis nodosa 10.3 CD40LG CD79A
18 mild pre-eclampsia 10.3 CD40LG CD79A
19 retinal microaneurysm 10.3 CD40LG CD79A
20 drug dependence 10.3 IL6 LTA TNF
21 pediatric meningioma 10.3 CD40LG CD79A
22 tonsil cancer 10.3 CD40LG CD79A
23 encephalitis 10.3 B2M MYOM2
24 indomethacin antenatal infection 10.3 CD40LG CD79A
25 bipolar i disorder 10.3 IL6 MYOM2 TNF
26 orthostatic proteinuria 10.2 IL6 LTA TNF
27 postcricoid region cancer 10.2 CD40LG CD79A
28 unilateral multicystic dysplastic kidney 10.2 IL6 TNF
29 human immunodeficiency virus infectious disease 10.2 CD40LG IL6 TNF
30 beach ear 10.2 CD40LG CD79A
31 adnp syndrome 10.2 IL6 LTA TNF
32 stomatitis 10.2 IL6 LTA MYOM2
33 acute kidney tubular necrosis 10.2 CD40LG CD79A
34 rift valley fever 10.2 IL6 LTA TNF
35 conduct disorder 10.2 CD40LG IL6 TNF
36 pancreatic signet ring cell adenocarcinoma 10.2 CD40LG IL6 TNF
37 mineral metabolism disease 10.2 CD40LG IL6 TNF
38 clostridium difficile colitis 10.2 CD79A IL6 TNF
39 tuberculosis 10.2 CD40LG IL6 TNF
40 atrophy of prostate 10.2 CD40LG IL6 TNF
41 mikulicz disease 10.2 CD79A IL6 TNF
42 carotenemia 10.2 CD40LG IL6 TNF
43 multiple myeloma 10.2
44 immunoglobulin g deficiency 10.2 CD40LG IL6 TNF
45 myiasis 10.2 CD40LG IL6 TNF
46 atheroembolism of kidney 10.2 CD40LG CD79A
47 bladder sarcoma 10.2 CD79A IL6 TNF
48 partial sensory epilepsy 10.2 CD40LG CD79A
49 depressed scar 10.2 CD40LG IL6 TNF
50 uterine adnexa cancer 10.2 CD40LG IL6 TNF

Graphical network of the top 20 diseases related to Monoclonal Gammopathy of Uncertain Significance:



Diseases related to Monoclonal Gammopathy of Uncertain Significance

Symptoms & Phenotypes for Monoclonal Gammopathy of Uncertain Significance

MGI Mouse Phenotypes related to Monoclonal Gammopathy of Uncertain Significance:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.09 B2M CD19 CD38 CD40LG CD79A IL6
2 homeostasis/metabolism MP:0005376 10.06 B2M CD19 CD38 CD40LG CD79A IL6
3 hematopoietic system MP:0005397 10.02 CD38 CD40LG CD79A IL6 LTA MAG
4 immune system MP:0005387 10 LTA MAF MAFB MAG TNF B2M
5 endocrine/exocrine gland MP:0005379 9.95 B2M CD38 CD40LG IL6 LTA MAFB
6 nervous system MP:0003631 9.7 B2M CD19 CD40LG CD79A IL6 LTA
7 liver/biliary system MP:0005370 9.63 TNF B2M CD19 CD79A IL6 LTA
8 renal/urinary system MP:0005367 9.1 CD19 CD40LG CD79A IL6 MAF MAFB

Drugs & Therapeutics for Monoclonal Gammopathy of Uncertain Significance

Drugs for Monoclonal Gammopathy of Uncertain Significance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Liraglutide Approved Phase 4 204656-20-2
2 Hormone Antagonists Phase 4,Phase 2,Phase 1
3 Hormones Phase 4,Phase 3,Phase 2,Phase 1
4 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
5 Immunoglobulins Phase 4,Phase 2,Phase 1
6 Antibodies Phase 4,Phase 2,Phase 1
7 glucagon Phase 4
8 Glucagon-Like Peptide 1 Phase 4
9 Hypoglycemic Agents Phase 4
10 Incretins Phase 4
11
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
12
Iron Approved Phase 3 7439-89-6 23925
13
Morphine Approved, Investigational Phase 3 57-27-2 5288826
14
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
15
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
16
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 22916-47-8 4189
17
Ondansetron Approved Phase 3 99614-02-5 4595
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
20
Dalteparin Approved Phase 3 9041-08-1
21
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
22
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
23
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
24
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
25 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
26 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
27 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
28 Anti-Infective Agents Phase 3,Phase 2,Phase 1
29 Antiemetics Phase 3,Phase 2,Phase 1
30 Antirheumatic Agents Phase 3,Phase 2,Phase 1
31 Autonomic Agents Phase 3,Phase 2,Phase 1
32 ferric gluconate Phase 3
33 calcium heparin Phase 3
34 pancreatic polypeptide Phase 3
35 Epoetin alfa Phase 3,Phase 2 113427-24-0
36 Analgesics Phase 3,Phase 2
37 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
38
Serotonin Phase 3 50-67-9 5202
39 Adjuvants, Anesthesia Phase 3
40 Serotonin Agents Phase 3
41 Serotonin Antagonists Phase 3
42 Narcotics Phase 3
43 Neurotransmitter Agents Phase 3,Phase 2
44 Hematinics Phase 3,Phase 2
45 Heparin, Low-Molecular-Weight Phase 3
46 Dermatologic Agents Phase 3,Phase 1,Phase 2
47 Analgesics, Opioid Phase 3
48 Tranquilizing Agents Phase 3
49 Anesthetics Phase 3
50 Anesthetics, General Phase 3

Interventional clinical trials:

(show top 50) (show all 92)
id Name Status NCT ID Phase
1 Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat Not yet recruiting NCT02920190 Phase 4
2 RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy Completed NCT00259974 Phase 3
3 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
4 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
5 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
6 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3
7 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
8 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
9 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
10 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
11 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
12 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
13 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
14 Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device Completed NCT01210716 Phase 3
15 The Treatment of Lenalidomide in Patients With POEMS Syndrome Unknown status NCT00971685 Phase 2
16 Beta Alethine in Treating Patients With Myeloma Unknown status NCT00006466 Phase 1, Phase 2
17 The Efficacy and Safety of ITF2357 in AIS Unknown status NCT00442182 Phase 2
18 Imaging in MGUS, SMM and MM Completed NCT01237054 Phase 2
19 Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma Completed NCT00099047 Phase 2
20 Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma Completed NCT00006219 Phase 2
21 Ilaris (Canakinumab) in the Schnitzler Syndrome Completed NCT01245127 Phase 2
22 Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias Completed NCT02041325 Phase 2
23 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2
24 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2
25 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2
26 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
27 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2
28 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2
29 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
30 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00245037 Phase 1, Phase 2
31 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2
32 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2
33 A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma Completed NCT01063907 Phase 1, Phase 2
34 Efficacy and Safety of Canakinumab in Schnitzler Syndrome Completed NCT01276522 Phase 2
35 Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) Completed NCT01045772 Phase 2
36 Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome Recruiting NCT02921893 Phase 2
37 Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients Active, not recruiting NCT02566265 Phase 2
38 Ilaris® Effects in Schnitzler Syndrome (ILESCH) Active, not recruiting NCT01390350 Phase 2
39 Daratumumab in Treatment of PGNIMD and C3 GN Not yet recruiting NCT03095118 Phase 2
40 Tocilizumab in Patients With Schnitzler's Syndrome Not yet recruiting NCT03046381 Phase 2
41 Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance Suspended NCT00665652 Phase 2
42 Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance Terminated NCT00588822 Phase 2
43 Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma Terminated NCT00942422 Phase 2
44 Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) Terminated NCT00899353 Phase 2
45 Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma Terminated NCT00538824 Phase 2
46 Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment Terminated NCT01548573 Phase 2
47 Imaging Studies and the Development of Multiple Myeloma Withdrawn NCT01571726 Phase 2
48 Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer Unknown status NCT00004036 Phase 1
49 A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Completed NCT01219010 Phase 1
50 Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients Completed NCT02267733 Phase 1

Search NIH Clinical Center for Monoclonal Gammopathy of Uncertain Significance

Genetic Tests for Monoclonal Gammopathy of Uncertain Significance

Anatomical Context for Monoclonal Gammopathy of Uncertain Significance

MalaCards organs/tissues related to Monoclonal Gammopathy of Uncertain Significance:

39
Bone, Bone Marrow, Testes, B Cells

Publications for Monoclonal Gammopathy of Uncertain Significance

Articles related to Monoclonal Gammopathy of Uncertain Significance:

(show all 15)
id Title Authors Year
1
CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance. ( 26303094 )
2016
2
The Immunotyping Distribution of Serum Monoclonal Paraprotein and Environmental Impact on Multiple Myeloma (MM) and Monoclonal Gammopathy of Uncertain Significance (MGUS) in Taiwan: A Medical Center-Based Experience. ( 26838245 )
2016
3
Nodular mucinosis associated with light-chain monoclonal gammopathy of uncertain significance. ( 27979308 )
2016
4
Autoantibodies against U1RNP and monoclonal gammopathy of uncertain significance: an unusual association. ( 19772812 )
2009
5
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. ( 17576818 )
2007
6
Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance. ( 17535272 )
2007
7
Paraovarian hemangioma with immunoglobulin deposits in a patient with monoclonal gammopathy of uncertain significance and osteolytic lesions. ( 15455229 )
2005
8
Prevalence of hepatitis C virus infection in IgM-type monoclonal gammopathy of uncertain significance and WaldenstrAPm macroglobulinemia. ( 15551289 )
2004
9
Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis. ( 15049904 )
2004
10
Myeloma and monoclonal gammopathy of uncertain significance associated with acquired von Willebrand's syndrome. Seven new cases with a literature review. ( 11858359 )
2002
11
Interleukin 6, tumour necrosis factor alpha and lymphotoxin alpha polymorphisms in monoclonal gammopathy of uncertain significance and multiple myeloma. ( 11167813 )
2001
12
Late blood pool images after Tc-99m tetrofosmin injection in a patient with monoclonal gammopathy of uncertain significance and immunologic disorders. ( 10885696 )
2000
13
Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. ( 9763553 )
1998
14
Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma. ( 8853167 )
1996
15
Erosive arthritis in monoclonal gammopathy of uncertain significance: report of four cases. ( 1747145 )
1991

Variations for Monoclonal Gammopathy of Uncertain Significance

Copy number variations for Monoclonal Gammopathy of Uncertain Significance from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13350 1 1 125000000 Gain Monoclonal gammopathy of undetermined significance
2 16482 1 125000000 249250621 Gain Monoclonal gammopathy of undetermined significance
3 55476 11 53700000 135006516 Gain Monoclonal gammopathy of undetermined significance
4 76533 13 32200000 40100000 Deletion NBEA Monoclonal gammopathy of undetermined significance
5 82835 14 17600000 107349540 Loss Monoclonal gammopathy of undetermined significance
6 89754 15 19000000 102531392 Gain Monoclonal gammopathy of undetermined significance
7 124088 19 1 26500000 Gain Monoclonal gammopathy of undetermined significance
8 166137 3 1 91000000 Gain Monoclonal gammopathy of undetermined significance
9 214491 6 61000000 171115067 Loss Monoclonal gammopathy of undetermined significance
10 253951 9 49000000 141213431 Gain Monoclonal gammopathy of undetermined significance

Expression for Monoclonal Gammopathy of Uncertain Significance

Search GEO for disease gene expression data for Monoclonal Gammopathy of Uncertain Significance.

Pathways for Monoclonal Gammopathy of Uncertain Significance

Pathways related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

(show all 26)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.17 B2M CD40LG IL6 LTA NCAM1 TNF
2
Show member pathways
12.65 B2M CD40LG IL6 LTA TNF
3
Show member pathways
12.54 CD40LG IL6 LTA TNF
4 12 B2M CD19 CD38 CD40LG CD79A NCAM1
5
Show member pathways
11.98 IL6 LTA TNF
6 11.96 CD40LG MAG NCAM1
7 11.92 B2M CD19 CD40LG
8 11.85 IL6 MAG TNF
9 11.79 IL6 LTA TNF
10
Show member pathways
11.77 IL6 LTA TNF
11 11.71 CD40LG LTA TNF
12 11.66 CD19 CD38 IL6 TNF
13
Show member pathways
11.65 CD40LG LTA TNF
14 11.62 LTA NCAM1 TNF
15 11.6 CD19 CD79A IL6 NCAM1
16
Show member pathways
11.58 CD40LG MAF TNF
17
Show member pathways
11.47 CD40LG IL6 TNF
18 11.43 CD19 CD38 IL6 NCAM1 TNF
19 11.4 CD40LG IL6 LTA TNF
20 11.38 CD19 CD38 CD40LG
21 11.3 CD40LG IL6 TNF
22 11.17 CD19 CD38 CD79A IL6 NCAM1 TNF
23 11.15 CD19 CD40LG CD79A
24 10.99 CD40LG IL6 LTA TNF
25 10.97 IL6 TNF
26 10.88 IL6 TNF

GO Terms for Monoclonal Gammopathy of Uncertain Significance

Cellular components related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 B2M CD38 CD40LG NCAM1 TNF
2 external side of plasma membrane GO:0009897 9.17 B2M CD19 CD40LG CD79A IL6 NCAM1

Biological processes related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.78 B2M CD38 IL6 LTA
2 immune response GO:0006955 9.77 B2M CD40LG IL6 LTA TNF
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.73 CD40LG IL6 TNF
4 tumor necrosis factor-mediated signaling pathway GO:0033209 9.72 CD40LG LTA TNF
5 cellular response to lipopolysaccharide GO:0071222 9.71 B2M IL6 TNF
6 B cell receptor signaling pathway GO:0050853 9.63 CD19 CD38 CD79A
7 positive regulation of chemokine production GO:0032722 9.52 IL6 TNF
8 negative regulation of growth of symbiont in host GO:0044130 9.51 LTA TNF
9 humoral immune response GO:0006959 9.5 IL6 LTA TNF
10 negative regulation of bone resorption GO:0045779 9.49 CD38 IL6
11 negative regulation of lipid storage GO:0010888 9.43 IL6 TNF
12 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.4 IL6 TNF
13 regulation of immunoglobulin secretion GO:0051023 9.26 CD40LG TNF
14 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.16 LTA TNF
15 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 8.96 LTA TNF
16 defense response to Gram-positive bacterium GO:0050830 8.92 B2M IL6 LTA TNF

Molecular functions related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 CD40LG IL6 LTA TNF
2 tumor necrosis factor receptor binding GO:0005164 8.8 CD40LG LTA TNF

Sources for Monoclonal Gammopathy of Uncertain Significance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....